Molecular Analysis of Disease Pathways

项目总结--总体 Cobre CMADP成立于2012年7月，旨在鼓励基础研究科学家开发和实施 用于研究与疾病有关的生物途径和应用过程的新的使能技术。完毕 在过去的九年里，CMADP的调查人员一直在进行与分子分析相关的健康相关研究 疾病的途径。到目前为止，我们已经通过研究支持和指导支持了24名初级教员。这个 到目前为止，从该项目毕业的18名教职员工获得了超过3850万美元的外部资金。 我们还建立了三个新的核心实验室，专注于疾病研究的使能技术： 基因组测序核心、合成化学生物学核心和KU纳米加工设施(前 微制造和微流体核心)。这三个核心带来了新的和必要的使能技术 到堪萨斯州，使我们能够吸引高质量的生物医学研究人员和教师到堪萨斯州来。因此，CMADP 加强了该州生物医学研究的人力和物力资源。此应用程序 要求为我们的科布雷中心第三阶段提供五年资金，以实现以下目标：(1)继续 越来越多的新的和持续的研究人员专注于分子的非常广泛的主题 疾病途径分析，(2)继续Cobre试点项目赠款的成功计划，该计划利用 我们的核心实验室，以及(3)通过扩展功能和用户基础来加强我们现有的核心实验室， 与科罗拉多州立大学研究办公室合作，根据以下几个方面的组合定位他们的长期可持续性 产生的费用加上大学的支持基础。结果将是一支非常强大的成功干部队伍 职业生涯中期的生物医学研究人员和自给自足的核心实验室，支持分子分析研究 全州范围内的疾病路径。我们坚信，CMADP对生物医学研究的总体影响 因此，KU和堪萨斯州将是实质性的和持久的。

PROJECT SUMMARY – OVERALL The COBRE CMADP was created in July 2012 to encourage basic research scientists to develop and implement new enabling technologies for the study of biological pathways and applied processes related to disease. Over the past nine years, CMADP investigators have pursued health-related research related to the molecular analysis of disease pathways. We have supported 24 junior faculty to date through research support and mentoring. The 18 faculty that have graduated from the program thus far have generated over $38.5 million in external funding. We also established three new Core Laboratories focused on enabling technologies for the study of disease: the Genome Sequencing Core, the Synthetic Chemical Biology Core and the KU Nanofabrication Facility (formerly the Microfabrication & Microfluidics Core). These three Cores brought new and essential enabling technologies to KU, allowing us to attract high-quality biomedical researchers and faculty to Kansas. As a result, CMADP strengthened both the human and the physical resources for biomedical research in the state. This application requests five years of funding for Phase 3 of our COBRE Center to pursue the following objectives: (1) to continue growing a critical mass of new and continuing investigators focused on the very broad theme of molecular analysis of disease pathways, (2) to continue a successful program of COBRE Pilot Project grants that utilize our Core Labs, and (3) to strengthen our existing Core Labs by expanding their capabilities and user bases, working with the KU Office of Research to position them for long-term sustainability based on a combination of fees generated plus a base of support from the University. The result will be a very strong cadre of successful mid-career biomedical research faculty and self-sustaining Core Labs that support research in molecular analysis of disease pathways statewide. We strongly believe that the overall impact of CMADP on biomedical research at KU and the state of Kansas will thus be substantial and enduring.